Multifocal Intraocular Lens Exchange in Patients with Ocular Comorbidities: Indications and Outcomes

Brian K Armstrong1,2*, Jason A Goldsmith1, Terrence Lee St. John3 and Samuel Navon1,2

1Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
2Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA
3Research Department, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates

*Corresponding Author: Brian K Armstrong, Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.

Received: April 24, 2021; Published: May 28, 2021

Abstract

Purpose: To investigate all cases of multifocal intraocular lens (MFIOL) exchange, with specific focus on indications for exchange and evaluation of postoperative outcomes, in a tertiary care, multi-specialty ophthalmology practice.

Setting/Venue: Academic Referral Center/Cleveland Clinic Abu Dhabi - Abu Dhabi, United Arab Emirates.

Methods: This retrospective case series identified all patients that presented to a large academic practice over a 4-year period that were intolerant to MFIOL technology and thus required intraocular lens (IOL) exchange. All patients reported poor vision despite correction of reversible ocular comorbidities, including dry eye and residual refractive error. Outcomes reviewed include subjective visual complaints, IOL-type, visual acuity, refractive error, ocular comorbidities, and surgical outcomes. Endpoints examined include mean uncorrected distance visual acuity (UDVA), mean corrected distance visual acuity (CDVA), mean refractive spherical equivalent (MRSE), and residual refractive astigmatism.

Results: Six eyes of five patients required MFIOL exchange. All IOL's exchanged were trifocal IOL's. IOL exchange occurred between 6 to 72 months following primary phacoemulsification. Each patient had multiple ocular comorbidities, ranging from keratoconjunctivitis sicca to longstanding intermediate uveitis and macular pathology. Postoperatively, subjective visual complaints resolved in all patients. Objective mean changes in UDVA, CDVA, MRSE and residual astigmatism were not statistically significant.

Conclusion: Thorough preoperative evaluation is required prior to MFIOL placement in order to rule out ocular comorbidities that may impair visual quality. In patients with MFIOL intolerance due to irreversible ocular comorbidities, IOL exchange to a monofocal IOL is safe, effective, and results in subjective improvement in vision.

Keywords: Multifocal IOL Intolerance; Trifocal IOLs; IOL Exchange; Ocular Comorbidities; Patient Dissatisfaction

Introduction

Multifocal intraocular lenses (MFIOLs) utilize a variety of optical designs to correct presbyopia in pseudophakic patients. Common MFIOLs, such as bifocal intraocular lenses (BIOLs), trifocal intraocular lenses (TIOLs) and extended depth of focus (EDOF) intraocular lenses (IOLs) work by diffracting light into 2 or 3 foci, or by providing a continuous range of focus, respectively. Of the MFIOL design variants, TIOL's provide the highest levels of spectacle independence because they enable excellent intermediate visual acuity (VA) without
adversely effecting distance or near VA [1-4]. However, there is evidence that some patients are intolerant of MFIOL technology, either due to ocular comorbidities that impact visual quality, bothersome photic phenomena or difficulty with neuroadaptation [5-8].

**Purpose of the Study**

The purpose of this study was to identify all cases of MFIOL exchange that occurred within an academic ophthalmology referral center over a specified time period, to investigate the reasons for IOL exchange, and to evaluate postoperative outcomes.

**Patients and Methods**

This retrospective chart review was performed with the approval of the Cleveland Clinic Abu Dhabi (CCAD) Institutional Review Board and conducted in accordance with the tenets of the Declaration of Helsinki. Patients and the public were not involved in the design, conduct, reporting, or dissemination plans of our research. A comprehensive electronic medical record review was conducted to identify all cases of MFIOL exchange at CCAD that occurred over a 4-year period from February 2015 through February 2019. The study included patients who had their cataract surgery performed at CCAD as well as patients that had surgery performed at outside facilities.

The data collected included patient demographics, ophthalmic history, type of primary MFIOL implanted, MFIOL fixation location, ocular comorbidities, surgical indication for IOL exchange, time interval between the surgeries, surgical complications, IOL exchange surgical technique, biometric method utilized, type of secondary IOL implanted, and postoperative follow-up range. Surgical indications were categorized as subjective visual symptoms such as blurred vision and/or photic phenomena (glares, halos, dysphotopsia).

Statistical analysis was performed using R version 3.5.1 statistical software (R Foundation, Vienna, Austria). Endpoints examined include mean uncorrected distance visual acuity (UDVA), mean corrected distance visual acuity (CDVA), mean manifest refractive spherical equivalent (MRSE) and residual refractive astigmatism. Sample mean and standard deviations were calculated for all pre- and postoperative time points. Inferential comparison of preoperative versus postoperative means were performed using paired-sampled t-tests. To provide context for the size of mean change observed pre- to postoperatively, standardized mean differences were calculated by dividing pre- and postoperative mean difference by the respective pooled standard deviation.

**Results**

We identified 6 eyes of 5 patients who underwent MFIOL exchange. All MFIOLs requiring exchange were AT LISA TIOL’s (Carl Zeiss Meditec, Jena, Germany); there were no other TIOL’s, BIOL’s or EDOF IOL’s that required explantation or exchange at CCAD during the study period. In 2 eyes of 2 patients, the primary AT LISA TIOL was initially implanted unilaterally at CCAD. In 4 eyes of 3 patients, the primary AT LISA TIOL was initially implanted at other medical facilities within the United Arab Emirates (UAE). Patient demographics are detailed in table 1. There were 3 females and 2 males included in the study, and the mean age at time of IOL exchange was 53 years (range 36 to 67 years). In all 6 eyes, the primary TIOL was implanted into the capsular bag during phacoemulsification surgery. Only one eye incurred an intraoperative complication, which was a limited anterior capsule tear during phacoemulsification.

<table>
<thead>
<tr>
<th>Eye</th>
<th>Age</th>
<th>Sex</th>
<th>Laterality</th>
<th>Date of Phaco</th>
<th>Facility</th>
<th>Phaco Complications</th>
<th>IOL</th>
<th>IOL Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>36</td>
<td>M</td>
<td>Right</td>
<td>1Jun’15</td>
<td>External</td>
<td>N/A</td>
<td>AT LISA TIOL</td>
<td>Capsule</td>
</tr>
<tr>
<td>#2</td>
<td>36</td>
<td>M</td>
<td>Left</td>
<td>15Jun’15</td>
<td>External</td>
<td>N/A</td>
<td>AT LISA TIOL</td>
<td>Capsule</td>
</tr>
<tr>
<td>#3</td>
<td>67</td>
<td>F</td>
<td>Right</td>
<td>15May’16</td>
<td>CCAD</td>
<td>N/A</td>
<td>AT LISA TIOL</td>
<td>Capsule</td>
</tr>
<tr>
<td>#4</td>
<td>53</td>
<td>F</td>
<td>Left</td>
<td>2012</td>
<td>External</td>
<td>N/A</td>
<td>AT LISA TIOL</td>
<td>Capsule</td>
</tr>
<tr>
<td>#5</td>
<td>64</td>
<td>F</td>
<td>Right</td>
<td>2012</td>
<td>External</td>
<td>Anterior Capsule Tear</td>
<td>AT LISA TIOL</td>
<td>Capsule</td>
</tr>
<tr>
<td>#6</td>
<td>62</td>
<td>M</td>
<td>Right</td>
<td>5Feb’17</td>
<td>CCAD</td>
<td>N/A</td>
<td>AT LISA TIOL</td>
<td>Capsule</td>
</tr>
</tbody>
</table>

CCAD = Cleveland Clinic Abu Dhabi, TIOL = Trifocal Intraocular Lens

**Table 1:** Demographics and phacoemulsification data.

Prior to IOL exchange, the mean logarithm of the minimal angle of resolution (logMAR) for UDVA and CDVA was 0.48 (range 0 to 0.88) and 0.11 (range -0.13 to 0.47) respectively. MRSE was -0.77 diopters (D) (range -0.25 to -1.63), and 5 of the 6 eyes had residual refractive astigmatism > 0.5D. Visual acuity, refractive error, subjective patient complaints and ocular comorbidities for each patient are shown in table 2.

<table>
<thead>
<tr>
<th>Eye</th>
<th>UDVA (Snellen)</th>
<th>Refractive Error</th>
<th>MRSE (D)</th>
<th>CDVA (Snellen)</th>
<th>UNVA</th>
<th>Visual Complaint(s)</th>
<th>Ocular Comorbidities</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>20/50</td>
<td>-1.75/0.75 x 155</td>
<td>-1.38</td>
<td>20/20</td>
<td>N/A</td>
<td>Blurred Vision Monocular Diplopia</td>
<td>Intermediate Uveitis, Keratoconjunctivitis Sicca, 1+ PCO, 360° Posterior Synechiae</td>
</tr>
<tr>
<td>#2</td>
<td>20/150</td>
<td>-2.00/0.75 x 25</td>
<td>-1.63</td>
<td>20/25</td>
<td>N/A</td>
<td>Blurred Vision Monocular Diplopia</td>
<td>Intermediate Uveitis, Keratoconjunctivitis Sicca, 1+ PCO</td>
</tr>
<tr>
<td>#3</td>
<td>20/40</td>
<td>-0.75/0.75 x 3</td>
<td>-0.38</td>
<td>20/25</td>
<td>J1</td>
<td>Blurred Vision</td>
<td>Interruption of ellipsoidal zone in the fovea, Dry Eye</td>
</tr>
<tr>
<td>#4</td>
<td>20/100</td>
<td>-1.25/1.5 x 178</td>
<td>-0.50</td>
<td>20/25</td>
<td>J3</td>
<td>Hazy Vision (Underwater vision)</td>
<td>Sjogrens Syndrome, 1+ PCO, Hydroxychloroquine Use</td>
</tr>
<tr>
<td>#5</td>
<td>20/80</td>
<td>-1.00/1.00 x 102</td>
<td>-0.50</td>
<td>20/60</td>
<td>J7</td>
<td>Blurred vision, Negative Dysphotopsia</td>
<td>Diabetic Macular Edema, Dry Eye, 1+ PCO</td>
</tr>
<tr>
<td>#6</td>
<td>20/20</td>
<td>-0.50/0.5 x 160</td>
<td>-0.25</td>
<td>20/15</td>
<td>J1</td>
<td>Positive Dysphotopsia (Haloes)</td>
<td>Increased HOA's, Increased Angle Kappa, Dry eye, Trace PCO</td>
</tr>
</tbody>
</table>

UDVA = Uncorrected Distance Visual Acuity, MRSE = Manifest Refractive Spherical Equivalent, D = Diopters, CDVA = Corrected Distance Visual Acuity, UNVA = Uncorrected Near Visual Acuity, PCO = Posterior Capsular Opacification, HOA = Higher Order Aberrations

Table 2: IOL exchange preoperative data.

Four out of 5 patients reported blurred vision in the operative eye at all distances (far, intermediate and near) that could not be ameliorated by treating reversible comorbidities, such as dry eye and residual refractive error. All eyes were found to have some degree of dry eye ranging from mild to severe, so dry eye treatment was initiated and escalated per an established dry eye management protocol [9]. All patients underwent manifest refraction and were either trial-framed or given full spectacle correction. The patients did not report satisfactory improvement in symptoms with either intervention. One patient reported positive dysphotopsia, manifesting as bothersome haloes around lights. Treatment with brimonidine tartrate 0.2% (Alphagan) eye drops as needed as well as blue light (470 nm) filtering eyeglasses (WellnessPROTECT Eyewear; Eschenbach, CT, USA) produced only mild improvement in symptoms.

All eyes had multiple ocular comorbidities, ranging from Sjogrens Syndrome with keratoconjunctivitis sicca to longstanding intermediate uveitis and macular pathology. Of note, 5 of the 6 eyes had mild posterior capsular opacification (PCO) on presentation. Nd:YAG laser capsulotomy was not undertaken in any eye given the multitude of comorbidities in each eye - comorbidities that decreased the likelihood that Nd:YAG laser capsulotomy alone would resolve the patient’s visual symptoms. Moreover, Nd:YAG laser capsulotomy was avoided due to the likelihood that these patients would require IOL exchange. IOL exchange in the setting of prior laser capsulotomy increases risk for...
Multifocal Intraocular Lens Exchange in Patients with Ocular Comorbidities: Indications and Outcomes

Intraoperative vitreous loss due to (a) the loss of compartmentalization of vitreous that is provided by an intact posterior capsule, and (b) rupture of the anterior hyaloid face by the laser treatment [10].

In all cases, the TIOL was exchanged for a monofocal IOL targeting emmetropia. Biometry was performed using the IOL Master 500 (V.7.7, Carl Zeiss Meditec) on the acrylic pseudophakia measurement setting. One case was calculated with the Holladay 1 formula on the IOL Master. One toric case was calculated using the Barrett Toric online calculator (V2.0; http://ascrs.org/barrett-toric-calculator). One case was calculated using the Holladay 2 formula on the IOL Master. The three remaining eyes were calculated with the Barrett Rx Exchange online calculator (V1.05; http://calc.apacrs.org/barrett_rx105/). Relevant parameters of IOL exchange are shown in table 3.

<table>
<thead>
<tr>
<th>Eye</th>
<th>Time Between Surgeries (Months)</th>
<th>IOL Exchange Formula</th>
<th>IOL Exchange Technique</th>
<th>Intraoperative Complications</th>
<th>Postoperative Complications</th>
<th>IOL Implanted</th>
<th>IOL Location Fixation</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>26</td>
<td>Barrett Rx Standard1 + Synchelalysis</td>
<td>Zonular Dehiscence</td>
<td>IOL Decentration</td>
<td>SN60WF</td>
<td>In the Bag</td>
<td></td>
</tr>
<tr>
<td>#2</td>
<td>26</td>
<td>Barrett Rx IOL Scaffold</td>
<td>Zonular Dehiscence</td>
<td>IOL Decentration</td>
<td>MA60AC</td>
<td>In the Bag</td>
<td></td>
</tr>
<tr>
<td>#3</td>
<td>6</td>
<td>Barrett Rx IOL Scaffold</td>
<td>Iris Sphincter Tear</td>
<td>N/A</td>
<td>SN60WF</td>
<td>In the Bag</td>
<td></td>
</tr>
<tr>
<td>#4</td>
<td>72</td>
<td>Holladay 1 IOL Scaffold</td>
<td>N/A</td>
<td>N/A</td>
<td>SN60WF</td>
<td>In the Bag</td>
<td></td>
</tr>
<tr>
<td>#5</td>
<td>72</td>
<td>Barrett Toric IOL Scaffold</td>
<td>N/A</td>
<td>N/A</td>
<td>SN6 AT4</td>
<td>In the Bag</td>
<td></td>
</tr>
<tr>
<td>#6</td>
<td>19</td>
<td>Holladay 2 Standard1</td>
<td>Zonular Dehiscence</td>
<td>Refractive Surprise</td>
<td>SN60WF</td>
<td>In the Bag</td>
<td></td>
</tr>
</tbody>
</table>

*Standard Technique is consecutive TIOL Bisection/Removal followed by IOL Insertion*

Table 3: IOL exchange data.

The mean time interval between phacoemulsification and IOL exchange was 36.8 months (range 6 to 72 months). IOL exchange was performed by two surgeons (B.K.A and J.A.G). A two-handed technique was utilized with extensive visco-dissection to free the plate haptics from capsular attachments. In 2 eyes, a standard technique was utilized, whereby the primary TIOL optic was cut into multiple pieces and removed from the eye prior to implanting the monofocal IOL. In the remaining 4 eyes, an IOL scaffold technique was used [11] whereby the primary TIOL was repositioned into the anterior chamber, and the monofocal IOL was placed into the capsular bag prior to bisecting and removing the TIOL from the eye.

The 2 most surgically challenging eyes were from the same patient with bilateral intermediate uveitis and severe capsular fibrosis. This patient had his initial phacoemulsification with bilateral TIOL placement performed outside CCAD. The right eye had 360° of posterior synechiae that required synchelalysis. Bilaterally, the TIOLs were encased within fibrotic capsular bags and dissection resulted in partial intraoperative zonular loss. The right eye required use of an Ahmed capsular tension ring (CTR) segment (FCI Ophthalmics, USA) that was scleral-sutured to improve centration and stabilization of the monofocal IOL in the capsular bag. The left eye required amputation and retention of one of the TIOL footplates. The 2 eyes with the longest duration of 72 months between initial phacoemulsification and IOL exchange experienced no intraoperative complications. Five of the 6 eyes eventually underwent Nd:YAG laser capsulotomy staged at least 3 months after IOL exchange.

IOL exchange outcome data are shown in table 4. The average follow-up interval for each patient was 28.8 months (range 14 to 41 months). The logMAR UDVA and CDVA were 0.17 (range 0 to 0.854) and 0 (range -0.12 to 0.10) respectively. Mean MRSE was -0.46D (range

Multifocal Intraocular Lens Exchange in Patients with Ocular Comorbidities: Indications and Outcomes

0.25 to -1.38) and only 2 eyes had residual refractive astigmatism > 0.5D. Subjective visual complaints resolved in all patients. UDVA and MRSE improved in each eye except for case 6 which had a refractive surprise of MRSE -1.38D. The patient was plano in the other eye and required no additional surgery after adaptation to monovision. All patients stated they would undergo IOL exchange again. Objective mean changes in UDVA, CDVA, MRSE and residual refractive astigmatism were not statistically significant. The results are shown in table 5.

<table>
<thead>
<tr>
<th>Eye</th>
<th>UDVA (logmar)</th>
<th>CDVA (logmar)</th>
<th>Refractive Cylinder</th>
<th>Spherical Equivalent</th>
<th>IOL Exchange Formula</th>
<th>Follow Up (Months)</th>
<th>UDVA (logmar)</th>
<th>CDVA (logmar)</th>
<th>Refractive Cylinder</th>
<th>Spherical Equivalent</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>0.40</td>
<td>0.00</td>
<td>0.75</td>
<td>-1.38</td>
<td>Barrett Rx</td>
<td>32</td>
<td>0.10</td>
<td>0.10</td>
<td>0.5</td>
<td>-0.50</td>
</tr>
<tr>
<td>#2</td>
<td>0.88</td>
<td>0.10</td>
<td>0.75</td>
<td>-1.63</td>
<td>Barrett Rx</td>
<td>32</td>
<td>0.18</td>
<td>0.00</td>
<td>0.25</td>
<td>-0.63</td>
</tr>
<tr>
<td>#3</td>
<td>0.30</td>
<td>0.10</td>
<td>0.75</td>
<td>-0.38</td>
<td>Barrett Rx</td>
<td>41</td>
<td>0.10</td>
<td>0.00</td>
<td>0.5</td>
<td>0.25</td>
</tr>
<tr>
<td>#4</td>
<td>0.70</td>
<td>0.10</td>
<td>1.50</td>
<td>-0.50</td>
<td>Holladay 1</td>
<td>21</td>
<td>0.10</td>
<td>-0.12</td>
<td>1.5</td>
<td>0.00</td>
</tr>
<tr>
<td>#5</td>
<td>0.60</td>
<td>0.48</td>
<td>1.00</td>
<td>-0.50</td>
<td>Barrett Toric</td>
<td>33</td>
<td>0.00</td>
<td>0.00</td>
<td>0.5</td>
<td>-0.50</td>
</tr>
<tr>
<td>#6</td>
<td>0.00</td>
<td>-0.12</td>
<td>0.50</td>
<td>-0.25</td>
<td>Holladay 2</td>
<td>14</td>
<td>0.54</td>
<td>0.00</td>
<td>0.75</td>
<td>-1.38</td>
</tr>
</tbody>
</table>

UDVA = Uncorrected Distance Visual Acuity, CDVA = Corrected Distance Visual Acuity

Table 4: IOL exchange outcome data.

<table>
<thead>
<tr>
<th>Endpoints</th>
<th>Pre-Operative</th>
<th>Post-Operative</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-Operative</td>
<td>Post-Operative</td>
<td>Mean Difference</td>
</tr>
<tr>
<td></td>
<td>Mean</td>
<td>Std Dev</td>
<td>Mean</td>
</tr>
<tr>
<td>Distance Visual Acuity</td>
<td>Uncorrected (logmar)</td>
<td>0.48</td>
<td>0.31</td>
</tr>
<tr>
<td>Corrected (logmar)</td>
<td>0.11</td>
<td>0.2</td>
<td>0</td>
</tr>
<tr>
<td>Manifest Refraction</td>
<td>Spherical Equivalent</td>
<td>-0.77</td>
<td>0.58</td>
</tr>
<tr>
<td>Refractive Cylinder</td>
<td>0.88</td>
<td>0.34</td>
<td>0.67</td>
</tr>
</tbody>
</table>

Table 5: Changes in visual acuity and refraction.

Discussion

MFIOLs increase spectacle independence in pseudophakic patients by correcting presbyopia. TIOLs are a subcategory of MFIOL that work by diffracting light into three separate focal points for distance, intermediate and near [1,2,4]. Appropriate patient selection, including exclusion of patients with many forms of irreversible ocular disease, is critical to success. TIOL technology has potential drawbacks, including photic phenomena and decreased contrast sensitivity in mesopic conditions [12,13]. Psychophysical halometry demonstrates that the double halo pattern produced by TIOL's tends to elicit fewer visual complaints than the single halo pattern produced by commercially-available BIOL's [14]. However, clinically significant haloes persist in approximately 40% of patients at a period of 3-6 months after TIOL placement [1,15,16] and can be bothersome in 5% of patients [16]. Studies also show that it may require 3 months for neuroadaptation to occur after MFIOL placement [6,17,18].

Although a wide variety of MFIOLs are implanted in the UAE, a comprehensive review of the CCAD electronic medical record system for MFIOL exchange of any IOL type revealed that the only MFIOL that required exchange during the study period was the AT LISA TIOL. The AT LISA combines a central 4.3 mm diameter trifocal area with a bifocal diffractive surface between 4.3 to 6 mm. The lens is available in both toric (model 939) and non-toric (model 839) versions and can come preloaded (MP) or non-preloaded (M). The AT LISA TIOL provides good contrast sensitivity and excellent uncorrected distance, intermediate and near visual outcomes in well-selected patient populations resulting in high rates of spectacle independence and patient satisfaction [1,15,18].

With regard to overall MFIOL available to our patients regionally, BIOLs were the first MFIOLs widely implanted in the UAE, but these patients represent only a small number of patients with MFIOL’s presenting to our practice. In 2012, the AT LISA was the first TIOL available in the UAE. The Panoptix IQ TIOL (Alcon Laboratories, Inc.) became available later in Fall 2014. As these newer IOLs emerged, the market shifted from BIOL to TIOL technology, and overall MFIOL implantation numbers are currently estimated to be in the thousands yearly. EDOF IOLs have more recently become available in UAE, but most were implanted after our designated study period. It’s important to note that our clinic cares for a substantial number of (both) expatriates and local patients who have participated in medical tourism abroad, where a larger variety of MFIOLs may have been implanted.

In this case series, 5 of 6 eyes presented with > 0.5D of residual refractive cylinder, which has been correlated with patient dissatisfaction after MFIOL placement [19,20]. Despite correcting refractive error with spectacle correction, none of our patients experienced subjective improvement in vision. We believe this is due to the presence of additional ocular comorbidities in our series of patients.

MFIOL implantation is contraindicated in the setting of ocular comorbidities that could further impact visual quality [5,21,22]. There is no evidence to suggest that TIOLs are any more or less forgiving relative to ocular comorbidities than BIOLs, as studies have shown equivocal outcomes related to contrast sensitivity outcomes between TIOLs and BIOLs [3,13,23]. Contraindications to BIOL and TIOL placement include, but are not limited to: corneal disease, untreated dry eye syndrome, abnormal/irregular tomography/topography, mydriasis/miosis, zonular instability/loss, macular disease and optic nerve disease [5]. Chronic or recurrent uveitis is an absolute contraindication for MFIOL placement, given this disease’s potential to negatively impact multiple parts of the ocular system. If there are potentially reversible comorbidities, such as untreated dry eye, map dot fingerprint dystrophy, pterygia or Salzmann nodules, we advise treating those conditions to resolution before consideration of MFIOL placement.

Corneal tomography is advised to check for abnormalities such as irregular astigmatism, increased higher order aberrations (HOA) and increased angle kappa. One of the patients in our series had -0.61 μm of horizontal corneal coma and angle kappa of 0.66 mm, as shown in figure 1. Following primary cataract surgery, this patient suffered from visually significant haloes that weren’t ameliorated by miotic drops or blue light (470 nm) filtering eyeglasses. It has been reported that coma values > ± 0.33 μm are problematic for MFIOL’s, as these patients may experience intolerable photic phenomena [24]. Alternatively, others recommend avoiding MFIOL technology when corneal HOAs exceed average ±2.00 SD of total HOAs, ± 0.30 μm of coma, ± 0.40 μm of trefoil, ± 0.30 μm of quatrefoil, ± 0.20 μm of fifth-order aberrations, or angle kappa is > 0.4 to 0.5 mm, as these abnormalities may decrease visual quality and increase the incidence of haloes and glare [25-27].

![Figure 1: Corneal tomography of eye #6 demonstrating increased angle kappa (*) and corneal coma (**).](image-url)
Preoperative dilated fundus examination and retina ocular coherence tomography (OCT) are advised to check for macular disease, as it is estimated that more than a quarter of patients undergoing phacoemulsification may have concurrent macular pathology [28]. Diabetes remains a relative contraindication to bifocal or TIOL technology, and there is no definitive guidance in this regard. We advise avoiding TIOL placement in any patient with diabetic retinopathy, diabetic macular edema and/or historical poor blood sugar control. If there is no evidence of diabetic retinopathy and a history of well-controlled blood sugars with adherence to diet and medication therapy, the surgeon and patient may consider TIOL placement. However, the patient should be informed that IOL exchange might be necessary if diabetic macular disease occurs in the future. One eye in this series had focal interruption in the ellipsoid zone in the fovea, as shown in figure 2. The patient complained of blurred vision at all distances after TIOL placement. In this particular case, the findings were only evident on retinal OCT, which has been shown to be more sensitive than stereoscopic retinal examination. Nearly 7 to 11% of normal-appearing retinas may harbor subtle macular pathologies that can only be reliably detected on OCT [29,30]. Although a preoperative screening OCT adds additional cost to cataract workup, it has been shown to be cost-effective by facilitating appropriate IOL selection by the patient and surgeon [29]. For cataract surgeons inexperienced with retinal OCT interpretation, this is one future potentially simple and useful application for artificial intelligence in the classification of normal from abnormal scans.

There are several published decision trees for managing patients that are intolerant to MFIOL placement [5-7]. The first step is to assess the subjective experience of the patient and to address his/her individual concerns [5]. Many problems can be effectively managed with a variety of minimally invasive treatment modalities specific to the complaint [7]. Second, treat reversible ocular comorbidities. A recent study by Seiler, et al [20] found that residual refractive astigmatism > 0.5D was the most common cause of patient dissatisfaction following placement of a TIOL. 26% of the eyes required subsequent selective wavefront-guided laser in situ keratomileusis to achieve satisfaction. We advise considering laser refractive correction if the patient improves with a trial of refractive correction but does not want to use spectacles or contact lenses. Dry eye syndrome is also a common confounder and we recommend initiating and escalating treatment per an established dry eye management protocol [9].

For patients experiencing bothersome photic phenomena, inhibition of mydriasis with topical brimonidine tartrate 0.2% on an as-needed basis can help to ameliorate the symptoms [7]. We have anecdotal experience suggesting that blue light filtering eyeglasses

---

**Citation:** Brian K Armstrong, *et al.* "Multifocal Intraocular Lens Exchange in Patients with Ocular Comorbidities: Indications and Outcomes*. EC Ophthalmology 12.6 (2021): 58-68.
(470nm) reduces photic phenomena in some patients. This is consistent with published findings demonstrating that blue-filtering IOLs may play a role in glare reduction in pseudophakic patients [31].

Clinically significant PCO is common after TIOL placement [32]. In a multi-center retrospective analysis looking at rates of Nd:YAG laser capsulotomy, investigators found the capsulotomy rates to be 23% following AT LISA placement [32]. Nd:YAG laser capsulotomy should be reserved until other potential problems have been ruled out and addressed, especially if the extent and density of the capsular opacity is disproportionate to the symptoms.

If there are ocular comorbidities that cannot be ameliorated, IOL exchange can be undertaken even years after initial IOL implantation [8]. For biometry prior to IOL exchange, we recommend using the Barrett Rx Exchange formula in cases where pre-phacoemulsification biometric data is available. This formula is derived from both the Barrett Universal II and Barrett Toric Calculator formulae. It calculates spherical power and, if needed, the optimal cylinder power and alignment of the new IOL [33]. Lacking historical data, one should use a 3rd generation IOL formula that does not estimate effective lens position (ELP) based on anterior chamber depth measurement (ACD). One eye in our study underwent calculation with the Holladay 2 formula on the IOL Master in the pseudophakia setting, but the ACD artificially overestimated ELP and resulted in myopic surprise.

IOL exchange can be challenging. The most common intraoperative complications include capsular rupture, vitreous loss and zonular rupture [10,34]. In this study, surgical complexity was highest in the 2 eyes from the same patient with bilateral intermediate uveitis and severe capsular fibrosis bilaterally. We recommend a bimanual surgical technique along with meticulous viscodissection and/or haptic amputation in cases of severe capsular contraction or fibrosis. In cases of zonular loss and capsular bag instability/decentration, be prepared to implement capsule support and refixation devices combined with scleral-fixation techniques in order to stabilize and re-center the IOL-capsular bag complex. Scleral-fixated capsular tension segments may be preferable to modified CTR’s, as fibroed capsular bags may not be amenable to placement of a CTR. The IOL scaffold technique has been shown to be safe and effective and can potentially reduce the risk for vitreous loss and posterior capsule rupture [11]. In cases of an open posterior capsule, this technique also prevents posterior dislocation of the IOL optic during transection [11]. Be prepared for anterior vitrectomy if vitreous presents and have a backup 3-piece IOL in case sulcus IOL placement is necessary. Alternatively, in the event that an IOL cannot be safely inserted into the capsular bag or sulcus, a scleral-fixated, iris-fixated, or anterior chamber IOL can be considered.

There are several limitations to this study. First, the AT LISA TIOL was the only MFIOL exchanged in our study. This study was conducted as a single-institution, retrospective chart review, whereas we know MFIOL’s are implanted and presumably exchanged elsewhere in the region. Thus, we are unable to calculate the comparative regional rate or overall incidence of MFIOL exchange within the scope of this study. Second, the sample size in this study is small. Although the improvement in standard mean differences from preoperative to postoperative UDVA, CDVA, MRSE and residual refractive error are quite large, we would need more eyes to demonstrate statistical significance. Third, neither contrast sensitivity assessment nor quality of vision surveys are routinely measured as a part of the clinical workup of patients in our clinic, so this quantitative data is not included in the analysis.

Although we know TIOL’s provide high levels of spectacle independence and patient satisfaction, our experience suggests that patient selection is critical to success, similar to other MFIOL’s. When patients are intolerant to MFIOL technology, particularly in the setting of irreversible ocular comorbidities, our results demonstrate that IOL exchange is an effective and safe surgical option. IOL exchange to a monofocal IOL resulted in subjective improvement in vision by the last follow up appointment in each of our patients.

Conclusion

Thorough preoperative evaluation is required prior to MFIOL placement in order to rule out ocular comorbidities that may impair visual quality. In patients with MFIOL intolerance due to irreversible ocular comorbidities, IOL exchange to a monofocal IOL is safe, effective, and results in subjective improvement in vision.
Author Contributions

BA was responsible for designing the study, collecting and analysing data, writing and submitting the article. JAG, TL and SN were responsible for designing the study, analysing data and editing the manuscript.

Funding Info

The authors have no relevant financial interests to disclose.

Competing Interests

The authors have no competing interests to disclose.

Data Availability

All data is included within the manuscript.

Ethics Approval

This study was approved by the Cleveland Clinic Abu Dhabi (CCAD) Institutional Review Board and conducted in accordance with the tenets of the Declaration of Helsinki.

Consent to Participate

Not Applicable.

Animal Research (Ethics)

Not Applicable.

Consent to Publish

All authors have agreed to the submission and publication of the paper in this journal.

Bibliography


**Citation:** Brian K Armstrong, et al. "Multifocal Intraocular Lens Exchange in Patients with Ocular Comorbidities: Indications and Outcomes". EC Ophthalmology 12.6 (2021): 58-68.
Multifocal Intraocular Lens Exchange in Patients with Ocular Comorbidities: Indications and Outcomes


Volume 12 Issue 6 June 2021
© All rights reserved by Brian K Armstrong, et al.